Filgrastim Injection
Filgrastim injection is a man-made protein that stimulates white blood cell production, used to reduce infection risk during chemotherapy, support recovery after bone marrow transplantation, treat severe chronic neutropenia, help collect stem cells, and improve survival after radiation exposure.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Filgrastim Injection: Patient Information Guide
A plain-language walkthrough of Filgrastim Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Filgrastim injection is approved for several conditions where the body's neutrophil (infection-fighting white blood cell) count is too low or needs to be boosted.
- Reduces the risk of serious infection (febrile neutropenia) in people with non-myeloid cancers receiving myelosuppressive (bone marrow-suppressing) chemotherapy
- Shortens the duration of low white blood cell counts and fever following induction or consolidation chemotherapy for acute myeloid leukemia (AML)
- Reduces the duration of neutropenia after myeloablative (high-dose, marrow-destroying) chemotherapy followed by bone marrow transplantation in people with non-myeloid cancers
- Mobilizes stem cells (hematopoietic progenitor cells) from the bone marrow into the bloodstream so they can be collected by a procedure called leukapheresis
- Treats severe chronic neutropenia — including congenital neutropenia, cyclic neutropenia, and idiopathic neutropenia — to reduce the frequency and severity of infections
- Neupogen is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
⚙️How it works▾
Filgrastim is a man-made version of G-CSF (granulocyte colony-stimulating factor), a protein your body naturally makes. It attaches to receptors on immature cells in the bone marrow and signals them to grow, multiply, and mature into neutrophils — the white blood cells that seek out and destroy bacteria. When chemotherapy or radiation wipes out the bone marrow's ability to make these cells, filgrastim steps in to restart production and keep your immune defenses working.
The boost in neutrophil count happens relatively quickly after dosing, and counts return toward baseline within about 4 days of stopping the medication. The neutrophils produced are fully functional — capable of hunting down bacteria and fighting infection normally.
💊How it's taken▾
Filgrastim is always given by injection — either as a subcutaneous (under-the-skin) shot or as an intravenous (IV) infusion into a vein. The route and frequency depend on why you are taking it: some uses call for a once-daily injection, others require twice-daily dosing or continuous IV infusion. For chemotherapy patients, it is started at least 24 hours after a chemotherapy dose and is never given within 24 hours before the next dose.
- For stem cell mobilization (Releuko): given by daily subcutaneous injection for at least 4 days before the first collection procedure
- For severe chronic neutropenia (Releuko): given by daily or twice-daily subcutaneous injection on an ongoing basis; the dose is adjusted based on blood count response
- For radiation exposure (Releuko): started as soon as possible after exposure and continued until white blood cell counts recover
If you miss a dose, contact your healthcare provider — do not double up without guidance. Always follow the instructions from your prescribing team and the medication guide included with your product.
🤒Side effects — in detail▾
The most common side effects of filgrastim include:
- Bone pain or muscle and joint aches — very common, especially during stem cell mobilization
- Fever (pyrexia)
- Headache
- Skin rash
- Fatigue
- Nausea
- Nosebleeds (epistaxis)
- Enlarged spleen (splenomegaly), particularly with long-term use
- Low platelet count (thrombocytopenia)
Serious reactions that require immediate medical attention include splenic rupture, acute respiratory distress syndrome (ARDS), severe allergic reactions (anaphylaxis), sickle cell crisis, kidney inflammation (glomerulonephritis), capillary leak syndrome, and aortitis (inflammation of the aorta). Contact your care team right away if you develop sudden abdominal or shoulder pain, difficulty breathing, or signs of a serious allergic reaction.
⚠️Warnings & precautions▾
- Splenic rupture: The spleen can rupture — sometimes fatally — in patients taking filgrastim. Sudden pain in the left upper abdomen or left shoulder is a red flag; seek emergency care immediately.
- Acute respiratory distress syndrome (ARDS): Filgrastim can cause ARDS, a severe lung condition. Tell your doctor right away if you develop fever with shortness of breath or lung problems.
- Severe allergic reactions: Anaphylaxis (a life-threatening allergic reaction) has occurred, most often with the first dose. Filgrastim must be permanently stopped if this happens.
- Sickle cell crisis: People with sickle cell disorders can experience severe, sometimes fatal, crises. Filgrastim should be stopped immediately if a crisis occurs.
- MDS and AML risk: Patients with congenital neutropenia on long-term filgrastim treatment have an increased risk of developing MDS (myelodysplastic syndrome) or AML (acute myeloid leukemia). Patients with breast or lung cancer using filgrastim with chemotherapy or radiation should also be monitored.
- Aortitis: Inflammation of the aorta (the body's main artery) has been reported, sometimes within the first week. Symptoms include fever, abdominal or back pain, and elevated inflammatory markers.
- Do not give at the same time as chemotherapy: Filgrastim must not be given within 24 hours before or after cytotoxic chemotherapy.
🔀What it interacts with▾
The FDA label for filgrastim does not list specific drug-drug interactions by name, but there are important timing and clinical considerations to be aware of:
- Cytotoxic chemotherapy: Filgrastim must not be given within the 24-hour window before or after chemotherapy — combining them can harm rapidly dividing bone marrow cells
- Radiation therapy: Simultaneous use with radiation therapy has not been studied and is not recommended
- Lithium: Not addressed in this label — always tell your prescriber about all medications, supplements, and herbal products you take
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not take filgrastim if you have had a serious allergic reaction to any filgrastim product or to pegfilgrastim — this is a contraindication (an absolute reason not to use it)
- Tell your doctor if you have sickle cell disease — filgrastim can cause severe and potentially fatal crises
- Tell your doctor if you have kidney disease — filgrastim is partly cleared by the kidneys; higher blood levels may occur with severe kidney impairment, though dose adjustment is generally not required
- Liver disease: dose adjustment for hepatic (liver) impairment is not necessary based on available data
- Pregnancy: available human data have not shown clear harm, but animal studies at high doses showed risks; discuss the benefits and risks with your doctor
- Breastfeeding: filgrastim passes into breast milk in small amounts and is poorly absorbed by infants; discuss with your doctor whether to continue breastfeeding
- Children: filgrastim is used in pediatric patients; for very small doses, the vial formulation should be used instead of the prefilled syringe to avoid dosing errors
- Older adults (65+): no significant differences in safety or effectiveness have been observed compared to younger patients
🚑If you take too much▾
The maximum safe dose of Neupogen has not been formally established. In clinical trials, very high white blood cell counts (above 100,000/mm³) occurred in fewer than 5% of patients but were not associated with serious harmful effects. If you think too much has been given, contact the Poison Help line at 1-800-222-1222 or seek medical care promptly.
📡Pharmacodynamics — effects in the body▾
After a dose of filgrastim, neutrophil counts in the blood rise in a dose-dependent way — meaning higher doses lead to higher counts. This effect is seen regardless of whether the drug is given intravenously or as a subcutaneous injection. When filgrastim is stopped, neutrophil counts return to pre-treatment levels in most patients within about 4 days. The neutrophils produced are fully functional, with normal ability to seek out and destroy bacteria.
🔬Pharmacokinetics — how your body processes it▾
Filgrastim is absorbed relatively quickly after a subcutaneous injection, reaching peak blood levels within 2 to 8 hours. After an intravenous dose, the drug has a half-life of roughly 3.5 hours — meaning the body clears about half of the drug in that time. The body processes filgrastim through two main pathways: receptors on white blood cells take up the drug (this pathway gets saturated at high levels), and the kidneys clear the remainder. Bioavailability (the fraction that reaches the bloodstream) after subcutaneous injection is 60–70%. The pharmacokinetics in children are similar to those in adults when doses are adjusted for body weight.
📦How to store it▾
Store NEUPOGEN vial refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light and physical damage. Avoid freezing NEUPOGEN vial; if frozen, thaw in the refrigerator before administration.
📄 Written from Filgrastim Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Filgrastim Injection
17 supplements and herbal products have documented interactions with Filgrastim Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 7
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Filgrastim Injection — the kind of thing our pharmacy team would talk through with you at the counter.
Why has my doctor prescribed filgrastim — what does it actually do for me? ▾
What side effects are most likely, and are they serious? ▾
How do I give myself the injection at home, and does it need to be refrigerated? ▾
Is it safe to take during pregnancy or while breastfeeding? ▾
Are there any medications or treatments I need to avoid while taking filgrastim? ▾
Is there anything special I should watch for that would mean I need to call my doctor or go to the ER? ▾
Is Filgrastim Injection available over the counter? ▾
When was Filgrastim Injection first available? ▾
Who makes Filgrastim Injection? ▾
💬 Answers drafted from Filgrastim Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Filgrastim Injection comes
Filgrastim Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Used to reduce the risk of febrile neutropenia (fever caused by dangerously low white blood cells) in people with cancer receiving myelosuppressive chemotherapy
- Used to shorten the period of low white blood cell counts after bone marrow transplantation or AML chemotherapy
- Neupogen is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation
- Used long-term in patients with severe chronic neutropenia (congenital, cyclic, or idiopathic) to reduce infections
- Releuko and Neupogen may be given by subcutaneous (under-the-skin) injection or by intravenous infusion, depending on the condition being treated — follow your prescriber's specific instructions
- Releuko: remove the vial or prefilled syringe from the refrigerator at least 30 minutes before injecting; do not leave it at room temperature for more than 24 hours
- Releuko prefilled syringe: direct administration of less than 0.3 mL is not recommended due to risk of dosing errors — use the Releuko single-dose vial for smaller doses
- Subcutaneous injections may be given in the outer upper arm, abdomen, thigh, or upper outer buttock — rotate sites and follow your healthcare provider's training before self-injecting
📊 Filgrastim Injection across the U.S. market
How Filgrastim Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Filgrastim Injection is used
A general measure of how commonly Filgrastim Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Filgrastim Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Filgrastim Injection prescribed? Of the 1,596 medications we measure, Filgrastim Injection ranks #724 by Medicaid prescriptions — more than 55% of them.
Utilization by Filgrastim Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
0.8 ML filgrastim-sndz 0.6 MG/ML Prefilled Syringe Most dispensed
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1605074
0.5 ML filgrastim-sndz 0.6 MG/ML Prefilled Syringe
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1605066
0.8 ML filgrastim-aafi 0.6 MG/ML Prefilled Syringe
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2057215
0.5 ML filgrastim-aafi 0.6 MG/ML Prefilled Syringe
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2057200
1 ML filgrastim 0.3 MG/ML Injection
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1649944
0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe
Summed across the 4 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1433771
0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 727535
0.5 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe
Summed across the 4 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1433768
0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 727544
0.8 ML filgrastim-ayow 0.6 MG/ML Prefilled Syringe
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2595961
0.5 ML filgrastim-ayow 0.6 MG/ML Prefilled Syringe
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2595944
1 ML filgrastim-aafi 0.3 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2057209
1.6 ML filgrastim 0.3 MG/ML Injection
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1649963
1 ML filgrastim-ayow 0.3 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2595953
1.6 ML filgrastim-aafi 0.3 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2057218
1 ML tbo-filgrastim 0.3 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2101456
1.6 ML tbo-filgrastim 0.3 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2101464
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Filgrastim Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 31 of 58 listed Filgrastim Injection NDCs with Medicaid activity.
🔍 Compare Filgrastim Injection products
A representative set of FDA-listed product records for Filgrastim Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 300 mcg/0.5 mL | Intravenous, Subcutaneous | Amgen, Inc × 3 listings | BLA | View NDC → |
| 300 mcg/mL | Intravenous, Subcutaneous | Amgen, Inc × 3 listings | BLA | View NDC → |
| 480 mcg/0.8 mL | Intravenous, Subcutaneous | Amgen, Inc × 3 listings | BLA | View NDC → |
| 480 mcg/1.6 mL | Intravenous, Subcutaneous | Amgen, Inc × 3 listings | BLA | View NDC → |
| 300 mcg/0.5 mL | Intravenous; Subcutaneous | Amgen Inc × 2 listings | BLA | View NDC → |
| 300 mcg/mL | Intravenous; Subcutaneous | Amgen Inc × 2 listings | BLA | View NDC → |
| 480 mcg/0.8 mL | Intravenous; Subcutaneous | Amgen Inc × 2 listings | BLA | View NDC → |
| 480 mcg/1.6 mL | Intravenous; Subcutaneous | Amgen Inc × 2 listings | BLA | View NDC → |
| 300 mcg/0.5 mL | Intravenous, Subcutaneous | Amneal Pharmaceuticals LLC | BLA | View NDC → |
| 300 mcg/0.5 mL | Intravenous; Subcutaneous | Amneal Pharmaceuticals LLC × 2 listings | BLA | View NDC → |
| 300 mcg/mL | Intravenous, Subcutaneous | Amneal Pharmaceuticals LLC | BLA | View NDC → |
| 300 mcg/mL | Intravenous; Subcutaneous | Amneal Pharmaceuticals LLC × 2 listings | BLA | View NDC → |
| 480 mcg/0.8 mL | Intravenous, Subcutaneous | Amneal Pharmaceuticals LLC | BLA | View NDC → |
| 480 mcg/0.8 mL | Intravenous; Subcutaneous | Amneal Pharmaceuticals LLC × 2 listings | BLA | View NDC → |
| 480 mcg/1.6 mL | Intravenous, Subcutaneous | Amneal Pharmaceuticals LLC | BLA | View NDC → |
| 480 mcg/1.6 mL | Intravenous; Subcutaneous | Amneal Pharmaceuticals LLC × 2 listings | BLA | View NDC → |
Showing 32 of 32 products — FDA National Drug Code Directory. See every product, package size and price: browse all 32 Filgrastim Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Filgrastim Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Filgrastim Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Filgrastim Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 68442 2 dose forms · 22 strengths
-
Dose form (SCDF) Injection RxCUI 1649943In current FDA listingsClinical drug / strength (SCD) 1 ML filgrastim 0.3 MG/MLRxCUI 16499441 ML filgrastim-aafi 0.3 MG/MLRxCUI 20572091 ML filgrastim-ayow 0.3 MG/MLRxCUI 25959531 ML tbo-filgrastim 0.3 MG/MLRxCUI 21014561.6 ML filgrastim 0.3 MG/MLRxCUI 16499631.6 ML filgrastim-aafi 0.3 MG/MLRxCUI 20572181.6 ML filgrastim-ayow 0.3 MG/MLRxCUI 25959591.6 ML tbo-filgrastim 0.3 MG/MLRxCUI 2101464 -
Dose form (SCDF) Prefilled Syringe RxCUI 727534No current FDA listingClinical drug / strength (SCD) 0.5 ML filgrastim 0.6 MG/MLRxCUI 7275350.5 ML filgrastim-aafi 0.6 MG/MLRxCUI 20572000.5 ML filgrastim-ayow 0.6 MG/MLRxCUI 25959440.5 ML filgrastim-laha 0.6 MG/MLRxCUI 27473510.5 ML filgrastim-sndz 0.6 MG/MLRxCUI 16050660.5 ML filgrastim-txid 0.6 MG/MLRxCUI 27003690.5 ML tbo-filgrastim 0.6 MG/MLRxCUI 14337680.8 ML filgrastim 0.6 MG/MLRxCUI 7275440.8 ML filgrastim-aafi 0.6 MG/MLRxCUI 20572150.8 ML filgrastim-ayow 0.6 MG/MLRxCUI 25959610.8 ML filgrastim-laha 0.6 MG/MLRxCUI 27473600.8 ML filgrastim-sndz 0.6 MG/MLRxCUI 16050740.8 ML filgrastim-txid 0.6 MG/MLRxCUI 27003780.8 ML tbo-filgrastim 0.6 MG/MLRxCUI 1433771
Look up RxCUI 68442 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Filgrastim Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Filgrastim Injection belongs to the Leukocyte Growth Factor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 2 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Amgen Inc is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.